Hikma Pharmaceuticals PLC (HKMPF.PK) Key Developments | Reuters.com
Edition:
United States

Hikma Pharmaceuticals PLC (HKMPF.PK)

HKMPF.PK on OTC Markets Group - US Other OTC and Grey Market

31.82USD
13 Jun 2016
Change (% chg)

-- (--)
Prev Close
$31.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
612
52-wk High
$38.00
52-wk Low
$25.00

Latest Key Developments (Source: Significant Developments)

Hikma Pharma reiterates guidance for 2016
Thursday, 12 May 2016 02:00am EDT 

Hikma Pharmaceuticals Plc : Hikma reiterates guidance for 2016 . Continue to expect full year group revenue to be in range of $2.0 billion to $2.1 billion . Remain on track to deliver global injectables revenue growth in mid to high-single digits in 2016 . Continue to expect injectables core operating margin to return to a more normalised level of around 36 pct . We expect branded revenue to be stronger in second half .Continue to expect 2016 revenue for combined generics to be in range of $640 million to $670 million.  Full Article

Hikma Pharmaceuticals Plc says US FDA closes out warning at Portugal plant - Reuters
Wednesday, 18 Nov 2015 02:30am EST 

Hikma Pharmaceuticals Plc:Hikma Pharmaceuticals Plc said it had received a letter from the U.S. Food and Drug Administration closing out a warning it received from the regulator last year on its injectables manufacturing plant in Portugal - RTRS.The Jordanian company, which makes and markets branded and non-branded generics and injectable drugs, said the letter demonstrates that the corrective actions taken at the plant were fully reviewed and accepted by the FDA - RTRS.The FDA had issued a warning letter to Hikma in October 2014 related to investigations and environmental monitoring at the company's plant in Portugal, where it produces powder, liquid and lyophilised injectable drugs - RTRS.  Full Article

Hikma to acquire cancer drug maker EIMC United Pharma
Tuesday, 8 Sep 2015 02:01am EDT 

Hikma Pharmaceuticals Plc:Hikma agrees to acquire EIMC United Pharmaceutical.Agreed to acquire 98.09 percent share capital of EIMC United Pharmaceuticals from a consortium of shareholders.  Full Article

Hikma Pharmaceuticals Plc declares interim dividend
Wednesday, 19 Aug 2015 02:00am EDT 

Hikma Pharmaceuticals Plc:Declares interim dividend of 11.0 cents per share (about 7.0 pence per share).Says interim dividend will be paid on Sept. 25, to eligible shareholders on register at close of business on Aug. 28.Says ex-dividend date is Aug. 27.  Full Article

Hikma Pharmaceuticals Plc announces acquisition of Roxane Laboratories Inc and Boehringer Ingelheim Roxane Inc
Tuesday, 28 Jul 2015 02:02am EDT 

Hikma Pharmaceuticals Plc:Says it has agreed to acquire Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. (together 'Roxane'), from Boehringer Ingelheim.Says Roxane is a US specialty generics company with a differentiated product portfolio and R&D capabilities.Says under the terms of the acquisition, on closing of the transaction Hikma will pay gross consideration of $1.18 billion in cash and will issue 40 million new Hikma shares to Boehringer (representing about 16.71 pct of Hikma's issued share capital immediately following closing and admission).  Full Article

Hikma Pharmaceutical reaffirms FY 2015 revenue guidance; comments on H1 2015 guidance
Thursday, 14 May 2015 02:01am EDT 

Hikma Pharmaceutical:Continue to expect FY 2015 group revenue growth of around 6 pct. in constant currency.Says on a reported basis, it expects FY 2015 group revenue growth of around 2 pct.Sees H1 2015 group revenue in constant currency to be broadly in line with the same period last year.  Full Article

Hikma Pharmaceutical launches caffeine citrate injection
Tuesday, 12 May 2015 04:00am EDT 

Hikma Pharmaceutical:Says it has launched CAFCIT Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL).CAFCIT is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.  Full Article

Hikma Pharmaceutical prices debut $500 million five-year eurobond
Wednesday, 1 Apr 2015 12:13pm EDT 

Hikma Pharmaceutical:Prices a Reg S $500 million 4.25 pct eurobond due April 2020.Proceeds will be used to refinance existing debt and for general corporate purposes.Bond will be listed on the Global Exchange Market of the Irish Stock Exchange.FCA/ICMA stabilisation applies.Says joint lead managers were Citi (Global Coordinator), Barclays, HSBC and National Bank of Abu Dhabi.  Full Article

Hikma Pharmaceuticals PLC gives FY 2015 revenue guidance in line with analysts' estimates
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Expects FY 2015 Group revenue growth of around 6 pct in constant currency.Reported revenue of $1.489 bln in FY 2014.FY 2015 revenue of $1.609 bln - Thomson Reuters I/B/E/S.  Full Article

Hikma Pharmaceuticals PLC recommends dividends
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Proposes final dividend of 15.0 cents per share, plus a special dividend of 6.0 cents per share.Proposed final dividend and final special dividend will be paid on May 21, 2015 to eligible shareholders on the register of Hikma at the close of business on April 17.  Full Article

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.